GSK Signs a Synthetic Lethality Cancer Agreement with Ideaya for ~$170M
Fulcrum Therapeutics Signs an Exclusive Worldwide License Agreement with GSK to Develop and Commercialize Losmapimod for Facioscapulohumeral Muscular Dystrophy
Shots:
- Ideaya to receive ~$100M as upfront in cash, $20M as equity investment, $50M in cash as option exercise fee for the MAT2A program and is eligible to receive preclinical, clinical, and commercial milestones
- The collaboration includes Ideaya’s synthetic lethality programs MAT2A, Pol Theta, and Werner Helicase programs, which are projected to reach clinical trials within the next 3yrs. Ideaya will lead the MAT2A program through early clinical development and is responsible for all costs of the MAT2A program prior to the GSK option exercise after that Ideaya is responsible for 20% of global development costs
- Ideaya will get equal profit share in the US and ex-US royalties for the MAT2A and Werner Helicase programs, global royalties for Pol Theta. GSK will cover all research, development, and commercialization costs and will be responsible for all commercialization activities and costs globally for licensed products
Click here to read full press release/ article | Ref: GSK | Image: Pharmaworld